Targeting the causes of muscle wasting in cancer patients
Targeting cancer cachexia drivers using antibody-based approaches
This study is looking at how cancer can cause severe muscle loss in patients, especially those with pancreatic cancer, and aims to find new ways to help prevent or treat this issue by exploring specific genes and potential therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10999442 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind cancer cachexia, a condition that leads to severe muscle loss in cancer patients, particularly those with pancreatic cancer. By studying specific genetic changes in mouse models, the researchers aim to identify new therapeutic approaches that could prevent or treat muscle wasting. The project focuses on understanding how certain genes influence the development of cachexia and how targeting these pathways with antibody-based therapies could improve patient outcomes. Ultimately, the goal is to develop innovative treatments that enhance the quality of life for patients suffering from this debilitating syndrome.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients, especially those diagnosed with pancreatic ductal adenocarcinoma who are experiencing symptoms of cachexia.
Not a fit: Patients with cancer who do not exhibit signs of cachexia or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve muscle mass and overall health in cancer patients experiencing cachexia.
How similar studies have performed: Previous research has shown promising results in understanding cancer cachexia, but this specific approach using antibody-based therapies is relatively novel.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Atfi, Azeddine — Virginia Commonwealth University
- Study coordinator: Atfi, Azeddine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.